BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9748121)

  • 21. Improved iodine radiolabels for monoclonal antibody therapy.
    Stein R; Govindan SV; Mattes MJ; Chen S; Reed L; Newsome G; McBride BJ; Griffiths GL; Hansen HJ; Goldenberg DM
    Cancer Res; 2003 Jan; 63(1):111-8. PubMed ID: 12517786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiolocalization of monoclonal antibodies in hepatic metastases from human colon cancer in congenitally athymic mice.
    Yoshida K; Rivoire M; Divgi C; Welt S; Cohen AM; Sigurdson ER
    Cancer Res; 1990 Feb; 50(3 Suppl):862s-865s. PubMed ID: 2297735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ; Archer GE; Wikstrand CJ; Bigner DD; Zalutsky MR
    Cancer Res; 1997 Apr; 57(8):1510-5. PubMed ID: 9108453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy.
    Blasberg RG; Nakagawa H; Bourdon MA; Groothuis DR; Patlak CS; Bigner DD
    Cancer Res; 1987 Aug; 47(16):4432-43. PubMed ID: 3607773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of daunomycin-antibody immunoconjugates in managing soft tissue sarcomas: nude mouse xenograft model.
    Stastny JJ; Das Gupta TK
    Cancer Res; 1993 Dec; 53(23):5740-4. PubMed ID: 8242630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
    Stein R; Govindan SV; Mattes MJ; Shih LB; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody.
    De Santis R; Albertoni C; Petronzelli F; Campo S; D'Alessio V; Rosi A; Anastasi AM; Lindstedt R; Caroni N; Arseni B; Chiodi P; Verdoliva A; Cassani G; Chinol M; Paganelli G; Carminati P
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2191-6. PubMed ID: 16609034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
    Foulon CF; Bigner DD; Zalutsky MR
    Bioconjug Chem; 1999; 10(5):867-76. PubMed ID: 10502355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate.
    LeBerthon B; Khawli LA; Alauddin M; Miller GK; Charak BS; Mazumder A; Epstein AL
    Cancer Res; 1991 May; 51(10):2694-8. PubMed ID: 2021947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production and characterization of two human glioma xenograft-localizing monoclonal antibodies.
    Wikstrand CJ; McLendon RE; Bullard DE; Fredman P; Svennerholm L; Bigner DD
    Cancer Res; 1986 Nov; 46(11):5933-40. PubMed ID: 3756930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
    Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27.
    Schrappe M; Bumol TF; Apelgren LD; Briggs SL; Koppel GA; Markowitz DD; Mueller BM; Reisfeld RA
    Cancer Res; 1992 Jul; 52(14):3838-44. PubMed ID: 1617657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors.
    Hornick JL; Khawli LA; Hu P; Sharifi J; Khanna C; Epstein AL
    Clin Cancer Res; 1999 Jan; 5(1):51-60. PubMed ID: 9918202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
    J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
    Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of humanized MAb 425 (EMD 62,000) in rats and specific localization in tumor-bearing nude mice.
    Steiner K; Haunschild J; Faro HP; Senekowitsch R
    Cell Mol Biol (Noisy-le-grand); 1995 Feb; 41(1):179-84. PubMed ID: 7773132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
    Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.